CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [ ], HAS BEEN OMITTED BECAUSE LIZHI INC. HAS DETERMINED SUCH
INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE
HARM TO LIZHI INC. IF PUBLICLY DISCLOSED.
FOIA CONFIDENTIAL TREATMENT REQUESTED
The entity requesting confidential treatment is
LIZHI INC.
Yangcheng Creative Industry Zone,
No. 309 Middle Huangpu Avenue,
Tianhe District, Guangzhou 510655,
The People’s Republic of China
+86 20 8381-8791
Rule 83 Confidential Treatment Request
November 4, 2019
BY HAND CONFIDENTIAL
Division of Corporation Finance
U.S. Securities and Exchange Commission 100 F Street, N.E.
Washington, D.C. 20549-7561
Attention: | Mr. Frank Knapp |
| Ms. Maryse Mills-Apenteng |
Re: | LIZHI INC. (CIK No. 0001783407) |
| Registration Statement on Form F-1 Filed October 28, 2019 |
Ladies and Gentlemen:
We are submitting this letter on behalf of LIZHI INC. (the “Company”) in connection with the review by the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) of the Company’s Registration Statement on Form F-1 (File No. 333-234351) (the “Registration Statement”).
Because of the commercially sensitive nature of the information contained herein, the Company respectfully requests that the specified information contained in this letter be treated as confidential information and that the Commission provide timely notice to Ms. Xi (Catherine) Chen, Chief Financial Officer of the Company, before it permits any disclosure of the bracketed information in this letter.
The Company respectively advises the Staff that, based on discussions with the Company’s board of directors and preliminary input provided by the underwriters for the offering, the Company anticipates that the price for this offering will be approximately US$[ ] per Class A ordinary share (the “IPO Price”)1. The indicative IPO Price represents an estimate of the fair value of the unrestricted, freely tradable shares that would be sold in the public market without liquidity and marketability discounts and is based on the management’s expectations of future profitability, as well as comparable companies’ valuations. The Company will include the actual price range in an amendment to the Registration Statement shortly before the commencement of the Company’s roadshow. That price range will be subject to then-current market conditions, continuing discussions with the underwriters and other factors that may affect the Company or the proposed offering. However, the Company believes that the foregoing indicative IPO Price will not differ significantly from the actual price range.
1 | The indicative IPO price per share is calculated on an as-converted (assuming conversion ratio of 1:1) and fully diluted basis with the Company’s pre-IPO valuation, including all the shares underlying all outstanding equity-based awards. |
1